1. LBA1_PRIMpassion130: Results from a global, randomised, double-blind, phase III study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC). (23rd October 2018) Authors: Schmid, P; Adams, S; Rugo, H S; Schneeweiss, A; Barrios, C H; Iwata, H; Dieras, V; Hegg, R; Im, S-A; Wright, G S; Henschel, V; Molinero, L; Chui, S Y; Funke, R; Husain, A; Winer, E P; Loi, S; Emens, L A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial. (13th September 2018) Authors: Colevas, A D; Bahleda, R; Braiteh, F; Balmanoukian, A; Brana, I; Chau, N G; Sarkar, I; Molinero, L; Grossman, W; Kabbinavar, F; Fassò, M; O'Hear, C; Powderly, J Journal: Annals of oncology Issue: Volume 29:Number 11(2018) Page Start: 2247 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗